Welcome to our dedicated page for Alcon news (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon stock.
Alcon Inc. reports developments in eye care through its Surgical and Vision Care businesses. Company news commonly covers quarterly results, constant-currency sales trends, product-launch momentum and portfolio updates across cataract and vitreoretinal surgical systems, intraocular lenses, contact lenses, lens-care products and ocular health.
Recurring updates also include launches and milestones for products such as Clareon, PanOptix, Vivity, TOTAL30, Precision7, Tryptyr and Unity, along with annual general meeting items, board elections, compensation votes, dividends, share repurchase authorizations, acquisitions, integration costs, R&D spending and other governance or capital-allocation actions.
Alcon (NYSE: ALC) reported fourth-quarter 2025 net sales of $2.7B, up 9% reported and 7% constant currency, and full-year sales of $10.3B, up 5% reported. Q4 diluted EPS was $0.44 (core diluted EPS $0.78). Operating income and margins declined amid launch investments and acquisition costs. Full-year free cash flow was $1.7B and the company returned $848M to shareholders.
Alcon (NYSE: ALC) launched TOTAL30 Multifocal for Astigmatism, the first monthly multifocal toric contact lens with Water Gradient Technology, now commercially available in the U.S. The lens reportedly delivers near 8/10 end-of-day comfort on day 30, 97% first-lens fit success, and fits nearly 90% of astigmatic presbyopes.
Available powers span +6.00 to -10.00 D with three ADDs and cylinder options 0.75–1.75; limited international rollout planned for 2026.
Alcon (NYSE: ALC) launched PRECISION7 in Canada on February 2, 2026, a one-week replacement sphere and toric contact lens featuring the world’s first ACTIV-FLO System that the company says continuously moisturizes the lens surface for seven days and delivers 16 hours of comfort and precise vision.
PRECISION7 joins Alcon’s WaterInnovations portfolio as a weekly alternative when daily disposables are not chosen for cost reasons, and will be commercially available in Canada starting February 2026.
Alcon (NYSE:ALC) announced completion of its $750 million share repurchase program that began on April 1, 2025. In aggregate, 9,301,877 registered shares were bought on the SIX Swiss Exchange, representing 1.9% of current share capital. The total buyback volume was CHF 602 million (USD 750 million). Acquired registered shares will be held in treasury and are intended to offset dilution from registered shares vesting under Alcon's equity-based incentive plans.
The program reduces outstanding shares and targets dilution from employee equity awards while using CHF cash resources.
Alcon (SIX/NYSE: ALC) announced on January 7, 2026 that it has terminated its definitive merger agreement to acquire STAAR Surgical (NASDAQ: STAA) that was announced on August 5, 2025. The company said it remained disciplined on price and risk and that its refractive strategy is unchanged, with a continued focus on its wavelight® plus offering for LASIK.
Alcon also said it will continue global launches of more than 10 major products across surgical and vision care this year and reiterated forward-looking caution about uncertainties and risks.
Broadwood Partners, which owns 30.2% of STAAR common stock (NASDAQ: STAA), thanked shareholders after preliminary results from the January 6, 2026 Special Meeting showed a decisive vote to reject the proposed acquisition of STAAR by Alcon (NYSE: ALC). Broadwood reiterated confidence in STAAR’s standalone prospects, citing leading technology, a strong financial position, large market opportunities, and a path to margin expansion.
Broadwood said it is ready to engage with the board and fellow shareholders to implement changes aimed at improving oversight and execution to help STAAR pursue growth and profitability as an independent company.
Alcon (SIX/NYSE: ALC) announced that CEO David Endicott will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 8:15 a.m. PST. A live webcast will be available at investor.alcon.com/news-and-events/events-and-presentations.
Alcon describes itself as the global leader in eye care with a heritage of over 75 years, serving more than 260 million people across 140 countries and employing over 25,000 associates. The release includes investor and media contact details for Geneva and Fort Worth offices.
Broadwood Partners, which owns 30.2% of STAAR common stock, criticized STAAR Surgical’s fourth postponement of the shareholder vote on the proposed sale to Alcon (NYSE: ALC).
The Special Meeting was rescheduled from December 19, 2025 to January 6, 2026. Broadwood called the transaction ill-advised, urged shareholders to vote AGAINST the deal, and said several large shareholders, all three proxy advisory firms, and at least one director have expressed skepticism about the process, timing, and price.
Alcon (SIX/NYSE: ALC) has exercised its right under the merger agreement to require STAAR Surgical (NASDAQ: STAA) to adjourn its Special Meeting of Stockholders.
The Special Meeting originally set for December 19, 2025 at 8:30 a.m. Pacific Time is adjourned to January 6, 2026 at 8:30 a.m. Eastern Time. The record date for eligible STAAR stockholders remains the close of business on October 24, 2025. Stockholders with voting questions should contact STAAR's proxy solicitor, Innisfree M&A Incorporated, using the provided phone numbers for stockholders and intermediaries.
Defender Capital (long‑term STAAR shareholder, ~1.5% stake) reiterated it will vote AGAINST STAAR Surgical's proposed sale to Alcon (NYSE: ALC) and criticized the board's pursuit of the transaction. Defender called the timing and price “wrong,” noted stabilization in Q2 results, cited Broadwood Partners' engagement, and highlighted governance concerns after the company delayed the shareholder vote to December 19 and reopened bidding.